XENE:NASDAQ, Xenon Pharmaceuticals Inc.

XENE stock overview

Xenon Pharmaceuticals Inc. (XENE:NASDAQ) closed at $37.04 on November 20, 2026, down 1.38% on the day. The stock trades 49.0% below its 52-week high of $72.66 and 11.0% above its 52-week low of $33.38. Over the past year, it lost 10.0%. Xenon Pharmaceuticals Inc. is part of the Health Care sector (Major Pharmaceuticals).

Key figures

Price
$37.04
Day change
-1.38%
Volume
1,090,768
Average volume
1,682,754
Market cap
3B+
52-week range
$33.38 – $72.66
50-day average
$39.45
200-day average
$52.21

Price action over the past year

In 252 trading sessions since November 20, 2025, XENE closed higher on 117 days (46%). Its best day was March 9, 2026 (+49.64%) and its worst was September 18, 2026 (-30.69%). The stock moved 10% or more in a single session 3 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

XENE news

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency. The company is also developing TV-45070, which is in Phase IIb clinical trials in patients with post-herpetic neuralgia; GDC-0276 and GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN801, a stearoyl Co-A desaturase-1 inhibitor that is in Phase II clinical trials in patients with moderate to severe facial acne. Its preclinical product candidate includes XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of childhood epilepsy disorders. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd.; Genentech, Inc.; uniQure Biopharma B.V.; and Merck & Co., In...

Similar stocks

Find more stocks like XENE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.